CN115916776A - 胶原蛋白1翻译抑制剂及其使用方法 - Google Patents

胶原蛋白1翻译抑制剂及其使用方法 Download PDF

Info

Publication number
CN115916776A
CN115916776A CN202180041881.XA CN202180041881A CN115916776A CN 115916776 A CN115916776 A CN 115916776A CN 202180041881 A CN202180041881 A CN 202180041881A CN 115916776 A CN115916776 A CN 115916776A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
branched
fibrosis
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180041881.XA
Other languages
English (en)
Chinese (zh)
Inventor
大卫·威廉·谢泼德
詹森·保罗·蒂尔尼
阿维亚德·曼达比
沃尔夫冈·施密特
斯特凡诺·莱万托
朱莉·尼科尔·汉布林
理查德·詹姆斯·布尔
艾里斯·阿尔罗伊
维萨姆·曼苏尔
莫蒂·科勒普菲什
王尧德
李海唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enimo Biotech
Original Assignee
Enimo Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enimo Biotech filed Critical Enimo Biotech
Publication of CN115916776A publication Critical patent/CN115916776A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202180041881.XA 2020-06-09 2021-06-09 胶原蛋白1翻译抑制剂及其使用方法 Pending CN115916776A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063036458P 2020-06-09 2020-06-09
US63/036,458 2020-06-09
PCT/US2021/036505 WO2021252555A1 (en) 2020-06-09 2021-06-09 Collagen 1 translation inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
CN115916776A true CN115916776A (zh) 2023-04-04

Family

ID=78845874

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180041881.XA Pending CN115916776A (zh) 2020-06-09 2021-06-09 胶原蛋白1翻译抑制剂及其使用方法

Country Status (8)

Country Link
US (1) US20230212131A1 (https=)
EP (1) EP4161921A4 (https=)
JP (2) JP2023529884A (https=)
CN (1) CN115916776A (https=)
AU (1) AU2021288584A1 (https=)
CA (1) CA3179059A1 (https=)
IL (1) IL298475A (https=)
WO (1) WO2021252555A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874697A (zh) * 2025-03-03 2025-04-25 成都大学 一种噻唑酰胺衍生物的制备方法和在治疗炎症中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20167018A7 (fi) * 2016-12-30 2018-07-01 Andras Kovacs Menetelmä ja laitteisto energian tuottamiseksi metalliseoksesta
WO2023111996A1 (en) 2021-12-17 2023-06-22 Reglagene Holding, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
PL4514782T3 (pl) 2022-05-19 2026-02-23 Astrazeneca Ab Związki amidoheteroaromatyczne przydatne w leczeniu chorób wątroby
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
IL310685B2 (en) * 2024-02-06 2026-02-01 Anima Biotech Inc Collagen-1 translation inhibitors and methods of using them

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040161A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
WO2006012642A2 (en) * 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
CN1938279A (zh) * 2004-01-30 2007-03-28 沃泰克斯药物股份有限公司 Atp－结合弹夹转运蛋白调控剂
CN101014597A (zh) * 2004-04-02 2007-08-08 沃泰克斯药物股份有限公司 可用作rock和其他蛋白激酶抑制剂的吖吲哚
WO2012082817A1 (en) * 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
CN102985418A (zh) * 2010-07-02 2013-03-20 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
WO2014059333A1 (en) * 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2016115463A1 (en) * 2015-01-15 2016-07-21 Whitehead Institute For Biomedical Research Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof
WO2017170860A1 (ja) * 2016-03-30 2017-10-05 東レ株式会社 ヒートショックプロテイン４７阻害剤
WO2017178174A1 (en) * 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
US20180177761A1 (en) * 2015-08-26 2018-06-28 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
CN110072857A (zh) * 2016-10-13 2019-07-30 葛兰素史密斯克莱知识产权发展有限公司 作为造血前列腺素d合酶抑制剂的1,3-二取代的环丁酮或氮杂环丁烷衍生物
CN111032662A (zh) * 2017-06-21 2020-04-17 尚医治疗有限责任公司 与ras超家族相互作用的用于治疗癌症、炎性疾病、ras蛋白病和纤维化疾病的化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000342A1 (en) * 1991-06-21 1993-01-07 Boehringer Mannheim Italia S.P.A. 2-amino-4-aryl-thiazoles with antiasthmatic and anti-inflammatory activities on the respiratory tract
EP1361220A4 (en) * 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
MXPA06000441A (es) * 2003-07-17 2006-04-05 Astellas Pharma Inc Derivado de 2-acilaminotiazole o sal del mismo.
FR2872813B1 (fr) * 2004-07-09 2007-01-19 Sanofi Synthelabo Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique
WO2007004038A1 (en) * 2005-07-05 2007-01-11 Pfizer Products Inc. Aminothiazole derivatives as agonists of the thrombopoietin receptor
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2009014674A1 (en) * 2007-07-23 2009-01-29 Sirtris Pharmaceuticals, Inc. Heterocyclylamides as gut microsomal triglyceride transport protein inhibitors
US8324385B2 (en) * 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
JP5705748B2 (ja) * 2009-02-18 2015-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調する複素環化合物
DE102011083283A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Heteroalkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Heteroalkylamidothiazolen
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
DE102013226711A1 (de) * 2013-12-19 2015-06-25 Beiersdorf Ag Verwendung von Alkylamidothiazolen in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
WO2017009650A1 (en) * 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
WO2017066225A1 (en) * 2015-10-14 2017-04-20 Texas Tech University System Pharmacoperones of the v2 receptor
WO2019028104A1 (en) * 2017-08-02 2019-02-07 Alphala Co., Ltd. NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
DE102018211412A1 (de) * 2018-07-10 2020-01-16 Beiersdorf Ag Selbstklebende flächige Produkte enthaltend ein oder mehrere Alkylamidothiazole
US20210380546A1 (en) * 2018-10-22 2021-12-09 The Regents Of The University Of California Vaccine adjuvant

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005040161A1 (en) * 2003-10-27 2005-05-06 S*Bio Pte Ltd Biaryl linked hydroxamates: preparation and pharmaceutical applications
CN1938279A (zh) * 2004-01-30 2007-03-28 沃泰克斯药物股份有限公司 Atp－结合弹夹转运蛋白调控剂
CN101014597A (zh) * 2004-04-02 2007-08-08 沃泰克斯药物股份有限公司 可用作rock和其他蛋白激酶抑制剂的吖吲哚
WO2006012642A2 (en) * 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents
CN102985418A (zh) * 2010-07-02 2013-03-20 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
WO2012082817A1 (en) * 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
WO2014059333A1 (en) * 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2016115463A1 (en) * 2015-01-15 2016-07-21 Whitehead Institute For Biomedical Research Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof
US20180177761A1 (en) * 2015-08-26 2018-06-28 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017170860A1 (ja) * 2016-03-30 2017-10-05 東レ株式会社 ヒートショックプロテイン４７阻害剤
WO2017178174A1 (en) * 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
CN110072857A (zh) * 2016-10-13 2019-07-30 葛兰素史密斯克莱知识产权发展有限公司 作为造血前列腺素d合酶抑制剂的1,3-二取代的环丁酮或氮杂环丁烷衍生物
CN111032662A (zh) * 2017-06-21 2020-04-17 尚医治疗有限责任公司 与ras超家族相互作用的用于治疗癌症、炎性疾病、ras蛋白病和纤维化疾病的化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
COLUMBUS, OHIO, US: "REGISTRY[Online]", 《REGISTRY》, 29 April 2011 (2011-04-29), pages 1 - 4 *
NARA LIESSI, ET AL.: "Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 144, 8 December 2017 (2017-12-08), pages 179 - 200, XP093141338, DOI: 10.1016/j.ejmech.2017.12.030 *
黄量: "《中国医学百科全书 药物学与药理学》", vol. 1, 31 October 1988, 上海科学技术出版社, pages: 12 - 13 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874697A (zh) * 2025-03-03 2025-04-25 成都大学 一种噻唑酰胺衍生物的制备方法和在治疗炎症中的应用

Also Published As

Publication number Publication date
CA3179059A1 (en) 2021-12-16
US20230212131A1 (en) 2023-07-06
JP2023529884A (ja) 2023-07-12
WO2021252555A1 (en) 2021-12-16
AU2021288584A1 (en) 2023-01-19
JP2026010018A (ja) 2026-01-21
EP4161921A4 (en) 2024-06-19
IL298475A (en) 2023-01-01
EP4161921A1 (en) 2023-04-12

Similar Documents

Publication Publication Date Title
CN113227068B (zh) Glp-1r激动剂及其用途
CN115916776A (zh) 胶原蛋白1翻译抑制剂及其使用方法
CA3078312A1 (en) Substituted fused tetra-cyclic 4-oxo-1,4-dihydropyridine derivatives and pharmaceutical compositions thereof useful for treatment of hbv
CN115427404B (zh) 胶原蛋白1翻译抑制剂和其使用方法
JP2019077729A (ja) Ｉｒａｋ４阻害剤としての二環式ヘテロシクリル誘導体
AU2014367284B2 (en) WNT pathway modulators
CN109890827A (zh) 螺环化合物
CN112204017B (zh) 苯并异噁唑化合物
WO2008100715A1 (en) Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
WO2022194269A1 (zh) 新型egfr降解剂
TW201534606A (zh) 醛固酮合成酶抑制劑
CN111601807A (zh) Menin-mll相互作用的外型-氮杂螺抑制剂
JP2025087798A (ja) コラーゲン１翻訳阻害剤およびその使用方法
US20240279215A1 (en) Nampt modulators
US20220370431A1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
CN114901640A (zh) 适用于治疗血脂异常的新型化合物
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
JP2025502899A (ja) Ｂｃｌ－２阻害薬
TWI919070B (zh) 醯胺雜芳香族化合物及其用途
JP2025521719A (ja) ｃ－ＭＹＣ ｍＲＮＡ翻訳調節因子及び癌治療におけるその使用
KR20250127267A (ko) 튜불린 중합 억제제
KR20240020201A (ko) 저산소증 유도 인자 1(hif-1) 억제제 또는 혈관내피성장인자(vegf)억제제 로서의 신규 화합물 및 이를 포함하는 약학적 조성물
HK40104970A (zh) 铁死亡调节剂、其制备和用途
HK40042077A (en) Hepatitis b capsid assembly modulators

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination